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Abstract  
Protection of neuronal homeostasis is a major 
goal in the management of neurodegenerative 
diseases. Microtubule-associated Ser/Thre 
kinase 2 (MAST2), inhibits neurite outgrowth, 
and its inhibition therefore represents a 
potential therapeutic strategy. We previously 
reported that a viral protein (G-protein from 
rabies virus) capable of interfering with 
protein–protein interactions between the PDZ 
domain of MAST2 and the C-terminal moieties 
of its cellular partners counteracts MAST2-
mediated suppression of neurite outgrowth. 
Here, we designed peptides derived from the 
native viral protein to increase the affinity of 
these peptides for the MAST2 PDZ domain. 
Our strategy involved modifying the length and 
flexibility of the non-interacting sequence 
linking the two subsites anchoring the peptide 
to the PDZ domain. Three peptides, Neurovita1 
(NV1), NV2, and NV3, were selected, and we 
found that they all had increased affinities for 
the MAST2 PDZ domain, with Kd values 
decreasing from 1300 to 60 nM, while target 
selectivity was maintained. A parallel 
biological assay evaluating neurite extension 
and branching in cell cultures revealed that the 
NV peptides gradually improved neural 
activity, with the efficacies of these peptides for 
stimulating neurite outgrowth mirroring their 
affinities for MAST2-PDZ. We also show that 
NVs can be delivered into the cytoplasm of 
neurons as a gene or peptide. In summary, our 
findings indicate that virus-derived peptides 
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targeted to MAST2-PDZ stimulate neurite 
outgrowth in several neuron types, opening up 
promising avenues for potentially using NVs in 
the management of neurodegenerative diseases. 
 
Introduction 
The stabilization of homeostasis and the 
promotion of neuron survival are major 
challenges in the treatment of 
neurodegenerative diseases and neuron 
protection after nerve damage. The PI3K/AKT 
signaling pathway mediates cell survival and 
promotes resistance to apoptosis by inactivating 
components of the apoptotic machinery (1,2). 
The PI3K/AKT signaling pathway also controls 
neuronal morphology and the dynamic 
formation of neurites during development. In 
mature neurons, the PI3K/AKT signaling 
pathway activates neurite extension and 
branching (referred to hereafter as neurite 
outgrowth).   
Neurite outgrowth is strongly repressed by 
inhibitory factors, such as PTEN (phosphatase 
and tensin homolog deleted on chromosome 
ten), an upstream inhibitor of the 
PI3K/AKT/mTOR cascade-signaling pathway 
(3-5). PTEN silencing restores neurite 
outgrowth in various types of neurons (6-9) and 
promotes branching (8,10,11) in cells and in 
vivo. Neurite outgrowth in human 
neuroblastoma cells (SHSY5Y) could be 
restored by the silencing of an AGC kinase 
widely expressed in the nervous system, the 
microtubule-associated serine-threonine kinase 
2 (MAST2) (12). The similar impacts of gene 
silencing observed for both PTEN and MAST2 
probably reflects the occurrence of protein-
protein interactions between these proteins, 
involving the PDZ domain (post-synaptic 
density protein 95, Drosophila disc large tumor 
suppressor and Zona occludens 1) of MAST2. 
Valiente and coworkers (13) showed that the 
PDZ domain of MAST2 (MAST2-PDZ) binds 
the C-terminal PDZ-binding motif (PBM) of 
PTEN, greatly increasing the phosphorylation 
of PTEN by MAST2 at sites thought to control 
both the cellular distribution and activity of 
PTEN. Through the formation of this binary 
complex, MAST2 and PTEN act in synergy to 
inhibit the signal transduction pathways 
required for neuronal survival, neurite 
outgrowth and regeneration (13-15). Specific 
disruption of the complex formed by MAST2-
PDZ and the PBM of PTEN would therefore be 
expected to block this inhibition, stimulating 
neuron survival, neurite outgrowth and 
regeneration.  
We previously showed that virulent strains of 
the rabies virus (RABV) promote the survival 
of infected neurons, through the binding of the 
C-terminus of the viral G protein to MAST2 via 
a PDZ/PBM interaction resembling that 
between PTEN and kinase (16). We have shown 
that the RABV G-protein of virulent strains 
promotes neurite outgrowth by activating the 
AKT signaling pathway in a PBM-dependent 
manner (16,17). Using NMR, we determined 
the high-resolution structures of the PDZ/PBM 
complexes formed by MAST2 and PTEN, and 
by MAST2 and RABV G-protein (18,19). The 
PBMs of RABV G-protein and PTEN both 
display an unconventional mode of binding to 
MAST2-PDZ involving two anchor sites and 
similar binding affinities enabling these 
proteins to compete at the binding site of 
MAST2-PDZ. Finally, we have shown that the 
expression of RABV G-protein in human 
neuroblastoma cells modifies the cellular 
distribution of PTEN in a PBM-dependent 
manner (18,19). Thus, the C-terminal sequence 
of RABV G-protein promotes neuron survival 
by disrupting the complex formed between 
MAST2-PDZ and PTEN. MAST2-PDZ appears 
to be a promising target for neuroprotective 
therapy. We aimed to design short interfering 
polypeptides capable of efficiently promoting 
neurite outgrowth by targeting MAST2-PDZ.  
In this article, we first identified the minimal 
core of the viral G-protein required for a peptide 
to trigger neurite outgrowth in different types of 
neurons after lentiviral vector-mediated 
transduction. Then, using the original PBM of 
the RABV G-protein (NV1-PBM) as our 
starting material, we performed a rational 
search for sequence modifications increasing 
the affinity of the PBM for MAST2-PDZ. We 
investigated the efficacy of three peptides — 
Neurovita1 (NV1), Neurovita2 (NV2) and 
Neurovita3 (NV3)—by comparing their 
capacities to trigger neurite extension and 
branching in neurons transduced with the 
corresponding lentiviral vectors. The affinity 
and specificity profiles of the NV-PBMs were 
checked with a collection of 222 human PDZ 
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domains (20). Finally, NV3-PBM was delivered 
to cells as a peptide after fusion to a cell-
penetrating molecule (CPM), as an alternative 
to lentivectors transduction with the aim to use 
it as a potential drug compound for 
neurodegenerative diseases, and the capacity of 
the peptide to stimulate neurite outgrowth was 
assessed. 
Results 
Relevance of the in vitro biological models we 
chose to study Neurovita properties  
The aim of the study is to analyze the biological 
properties of different sequences of Neurovita 
based on the basis of the strength of their 
interaction with the PDZ of MAST2. Thus, it is 
required that the selected cell models used in the 
biological assays do express MAST2. MAST2 
expression was detected by Q-PCR in human 
neuroblastoma, mouse primary cells and rat 
neuroscreen (NS) cells, (Fig S1A) and by 
immunocytochemistry using a specific MAST2 
antibody in human neuroblastoma and rat NS 
(Fig S1B). In addition, we confirmed that 
MAST2 silencing in the human SH-SY5Y 
neuroblastoma cell line used in our laboratory 
stimulates neurite outgrowth (Fig 1A) as 
previously shown by Loh S et al (12).  
 
Construction of the initial Neurovita 1 (NV1) 
peptide 
The infection of neurons with RABV leads to 
the expression of five viral proteins, the N, M, 
G, NS and L proteins. The G-protein, (Fig. 1B 
Diagram of the full-length RABV G-protein) is 
a 524 aa type I glycoprotein. It is synthesized in 
the endoplasmic reticulum (ER) of the soma, 
and is then glycosylated in the Golgi apparatus 
(see G protein trafficking in Fig.1B). The G- 
protein then migrates to the plasma membrane 
of the neurites, where it associates with the viral 
RNP and M protein, for virion formation and 
egress by budding. The G-protein is attached to 
ER and plasma membranes via its unique 
transmembrane domain (TM). The ectodomain 
(EC) of the G-protein is located within the 
luminal compartment of the ER initially, and 
then at the cell surface after fusion to the plasma 
membrane. During G-protein trafficking from 
the ER to the plasma membrane, the 
cytoplasmic domain (Cyto) containing the C-
terminal PBM is always exposed to the 
cytoplasm of the somato-dentritic neuronal 
area, where it can interact with cellular partners 
such as MAST2, via its PDZ domain. The 
formation of this complex triggers 
neurosurvival signaling pathways and the 
localization of MAST2 to a submembrane area 
of the infected cells (16). 
We identified the parts of the viral G-protein 
required for a short interfering polypeptide to 
mimic the neurosurvival properties of the viral 
G-protein. We constructed a mini-RABV G- 
protein, NV1, (Fig. 1B, NV1 scheme). NV1 
harbours a 99.6% deletion of the EC domain but 
retains the SP, TM and Cyto-PBM domains, 
which are required for its processing. We 
investigated the role of the C-terminal PBM in 
the biological properties of NV1 by generating 
a polypeptide lacking four aa at the C-terminus, 
NV1delta (NV1) (Fig.1B NV1 scheme). The 
properties of the NVs were investigated 
following the transduction of two types of 
neuronal cell lines: SH-SY5Y cells and NS. The 
NV1 and NV1 proteins were detected by 
western blotting (WB) with a specific Cyto-G 
antibody in SHSY5Y cell lysates 24 h after 
transduction (Fig. 1C) and in NS cell lysates 48 
h after transduction (Fig.1D). Neurite 
outgrowth in NV1-transduced cells was 
similar to that in non-transduced cells (Fig. 1 C 
and D). By contrast, NV1 triggered a significant 
stronger neurite outgrowth by comparison to 
NV1 in both types of cell [1.6 times stronger 
in SHSY5Y cells 30 h after transduction, and 
3.1 times stronger in NS cells 72 h after 
transduction (Fig. 1C and D, right panels and 
Fig S2 for NeuronJ drawings].  
Neurite outgrowth was also triggered in neurons 
other than neuroblastoma and 
pheochromocytoma cells grown in the presence 
of a DF medium (NGF or db-cAMP for NS and 
SHSY5Y, respectively). The effects of NV1 
were assessed in transduced human IPSc 
derived motor neurons (Fig. 2A), and in 
transduced E16 mouse primary cortical neurons 
(Fig. 2B). In these two models, where lentivirus 
transduced more than 80% of cells (data not 
shown), NV1 stimulated neurite outgrowth 
more efficiently than NV1(1.8-fold increase 
in human motor neurons and 1.2-fold increase 
in primary mouse cortical neurons). Thus, NV1 
induces neurite outgrowth in a PBM-dependent 
manner in primary cultures of neurons, whether 
of mouse and human origin. 
These results show that it is feasible to construct 
a polypeptide conserving the properties of the 
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viral G protein if this polypeptide includes the 
cytoplasmic part of the G protein and the last 4 
aa from the C-terminus of the PBM. 
Optimization of NV-PBMs sequences to 
improve their binding to MAST2-PDZ 
We previously solved the high-resolution 
structures of the C-terminal sequences of 13 
residues of PTEN and RABV G-protein bound 
to MAST2-PDZ and calculated their affinities 
(1.99 and 1.26 µM, respectively) (19). We 
discovered that, unlike most PBMs, the PBMs 
of PTEN and of viral G protein have an 
unusually large interaction surface (700Å2), 
encompassing not only the 4 aa at the C-
terminus of the PBM (-QTRLCOOH for G protein 
and -ITKVCOOH for PTEN), but also a second 
anchoring region located at the N-terminus of 
the assayed peptides, (NH2SW- for G protein and 
NH2PF- for PTEN), (Fig. 3A). The sequences 
interacting with MAST2-PDZ are 
NH2SWESHKSGGQTRLCOOH and 
NH2PFDEDQHTQITKVCOOH for G protein and 
PTEN, respectively. They contain three 
contiguous regions, the N-terminal anchor (2 aa 
residues in blue in Fig. 3), a linker (7 aa residues 
in green) and the conventional C-terminal 
anchor (4 aa residues in orange).  
We began our search for peptides with a greater 
affinity for MAST2-PDZ by focusing on the 13 
residues at the C-terminal end of the viral G 
protein (SWCyto 13QTRL) and human PTEN 
(PFPTENITKW). Using our high-resolution NMR 
structures of MAST2-PDZ/peptide complexes, 
we rationally designed sequences likely to 
increase the enthalpic contribution and decrease 
the entropic cost of binding to MAST2-PDZ. 
Isothermal titration calorimetry was performed 
in binding experiments with the MAST2-PDZ 
domain; the thermodynamic quantities 
associated with peptide binding were compared 
with the data obtained for the original sequences 
(18,19). 
We focused on optimizing the seven-residue 
linker (positions -4 to -11) tethering the N-
terminal and C-terminal anchors of viral G-
protein onto MAST2-PDZ, which has been 
shown to be a sensitive target for improving 
binding affinity(18) (21). By contrast, we kept 
the C-terminal anchor -QTRLCOOH, which 
maintains specificity, intact, together with the 
N-terminal dipeptide NH2SW-, which 
significantly increases binding affinity. 
 We began by maintaining linker length at seven 
residues and mutating exposed residues to 
increase the degree of hydrophobic contact of 
the two original linker sequences [S(-6) and K(-
7) for SW Cyto13QTRL or D(-8), and D(-10) for 
PFPTENITKV] (Fig. 3B).  
These modifications increased affinity 
modestly with respect to SWCyto13QTRL, by a 
factor of three at best (Fig. 3B). This was not 
unexpected, because, for all assayed sequences 
with a linker of this length, any decrease in the 
free enthalpy of binding is strongly 
compensated by a simultaneous decrease in the 
associated entropy. The mean compensation 
between these two thermodynamic quantities 
was estimated at 80% from the slope of the plot 
of the corresponding data displayed in Fig. 3C.  
By analyzing the kinetic behavior of potential 
candidates with seven-residue linkers, we 
previously showed (18) that the flexibility of 
linker sequences strongly affects their affinity 
for MAST2-PDZ. However, the high-resolution 
3D structures of the PDZ/PBM complexes 
provided no evidence of contact between 
MAST2-PDZ and the linker present in the 
Cyto13 of viral G protein or PTEN. This 
discrepancy was probably mostly due to the 
conformational entropy of the potential ligand 
in the unbound state, because the polypeptides 
most disordered when free in solution were the 
poorer binders. We therefore reduced linker 
length from 7 to 5 aa and designed seven new 
sequences, for which we compared binding 
abilities (lines 5 to 11 in Fig. 3B). The deletion 
of 2 aa from sequence 442 to generate sequence 
441 led to a significant increase in the entropy 
of binding with no marked change in enthalpy 
contribution, resulting in a four-fold increase in 
affinity. For these shorter sequences, the 
compensation between the enthalpy and the 
entropy terms remained at 80% (Fig. 3C). The 
binding affinities of the new candidates were 
also modulated by the substitution of one or 
both of the doublet glycine present at positions 
-4 and -5. The G to Q change at position -4 
yielded the candidate with the highest affinity, 
PBM 454. 
We retained the two sequences with the highest 
affinities from this second step in peptide 
design: PBM 441 (which we named NV2-PBM) 
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and PBM 454 (which we named NV3-PBM). 
Affinity was 10 times higher than that of the 
starting sequence (NV1-PBM) for NV2-PBM 
(Kd of 120 nM) and 20 times higher for NV3-
PBM (Kd of 60 nM). The kinetics of binding for 
NV1-PBM (original sequence) and NV3-PBM 
(sequence with the highest affinity) were 
compared in stopped-flow experiments. For 
NV3-PBM, we were able to obtain an accurate 
value for the association rate constant (1.4x107 
M-1.s-1, a 1.6-fold increase with respect to NV1-
PBM). We could obtain estimates only for the 
very slow dissociation process, with an 
approximate dissociation rate constant of 0.89 s-
1, more than one order of magnitude higher than 
the corresponding values for the other peptides 
tested, such as the original PBM, PTEN-PBM 
(9.7 s-1)  and NV1-PBM (16.6 s-1). The 
residence time of NV3-PBM on the MAST2-
PDZ domain was 1.1 seconds, a value 10 times 
greater than that for the initial NV1-PBM 
sequence. 
Affinity profiles of the three NV sequences 
We addressed the issue of PDZ-NV-PBM 
specificities by performing automated holdup 
assays (20). We used this high-throughput 
chromatographic approach to quantify PDZ-
PBM interaction affinities at equilibrium in 
solution for a collection of 222 human PDZ 
domains, corresponding to 83% of the original 
PDZome (266 PDZ domains) overexpressed in 
a soluble form. The holdup screens probing the 
interaction of the PDZome with NV1-, NV2- 
and NV3-PBM, were performed in triplicate. In 
Fig. 4, the PDZ binding intensities (BI) of NV-
PBMs are ranked in descending order from left 
to right. Using a stringent BI threshold of 0.2 to 
retain only high-confidence binding pairs, the 
holdup assay identified 5, 8 and 15 hits for 
NV1-PBM, NV2-PBM and NV3-PBM, 
respectively. The PDZ domains recognized by 
NV1-PBM also bound to NV2-PBM. The NV2-
PBM binders were also included in the set of 
proteins recognized by NV3-PBM. The number 
of binders detected increased with affinity for 
MAST2-PDZ, but the slope of BI decay in the 
binding profiles indicated that recognition 
specificity was roughly maintained from NV1-
PBM to NV3-PBM. Furthermore, this affinity-
based ranking demonstrated that all three NV-
PBMs targeted MAST2-PDZ preferentially 
among the 222 PDZ domains tested.  
Comparison of the biological activities of NV 
constructs in NS cells  
Mini-G sequences encoding NV2-PBM or 
NV3-PBM were constructed as described (Fig. 
5A). They were delivered to NS cells by 
lentivirus vectors. The viability of the three 
lentivirus vectors encoding NV1, NV2 and NV3 
was demonstrated by quantifying NV 
transcripts in the transduced NS cells (Fig. 5B, 
left panel). Each viral vector produced similar 
amounts of the corresponding NV1, NV2 and 
NV3 polypeptides, as shown by WB (Fig. 5B, 
right panel). We then compared the effects on 
neurite outgrowth of NV1, NV2 and NV3 in NS 
cells, 72 h after transduction (Fig. 5C and Fig. 
S2 for NeuronJ drawings). Peptide rankings for 
the stimulation of neurite outgrowth 
(NV3>NV2>NV1) were identical to those 
obtained in vitro for affinity for MAST2-PDZ.  
 We then analyzed whether the greater capacity 
of NV3 and NV2 to stimulate neurite outgrowth 
was associated with a greater complexity of 
neurite arborization. We performed Sholl 
analysis (22) to determine how many times the 
neurites of a given cell crossed concentric 
circles of increasing radius centred on the cell 
soma. The results of the analysis are expressed 
as the mean number of neurites crossing each 
circle of increasing radius from 0 to 250 µm for 
NS cells transduced with each type of construct 
and for non-transduced cells (Fig. 5D). The 
expression of the various NVs was associated 
with a significant increase in neurite 
arborization complexity relative to that for non-
transduced cells, even though the increase 
between arborization triggered by NV1 and 
NV2 stays modest. As already shown above for 
the neurite outgrowth phenotype, NV3 yielded 
the best increase in arborization.  
Practical impact on drug design The NVs were 
expressed in neurons via lentiviral vector 
transduction. However, this type of 
vectorization is not optimal for human 
therapeutic applications, thereby alternative 
way to deliver NV need to be considered. 
Peptide delivery is a possible option, only if two 
criteria are respected: a) the active sequence is 
coupled with a cell-penetrating molecule, CPM, 
to facilitate passage across the outer membrane 
of the neurons and b) the entire polypeptide size 
remains small to facilitate its production.  
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We reduced the size of the most active peptide 
NV3, by restricting the peptide to its 
cytoplasmic domain (NV3-Cyto). A new 
lentiviral vector, NV3-Cyto, was designed, to 
determine whether the removal of the part of the 
sequence responsible for endomembrane 
anchorage (the SP, two amino acids of the EC 
and the TM domain) could be tolerated (Fig. 
6A). We assessed lentivector viability for NV3 
and NV3-Cyto by performing RT-PCR on NS 
cells after transduction (Fig. 6B). NS cells 
transduced with NV3-Cyto displayed neurite 
outgrowth, but less than that observed with the 
parental peptide NV3 (Fig.6C). Unlike cells 
transduced with the parental peptide, the cells 
transduced with NV3-Cyto were unable to 
achieve higher levels of branching (data not 
shown). The properties of NV3-Cyto-
transduced cells were similar to those of cells 
transduced with the initial construct, NV1 (as 
shown in Fig. 6C for neurite outgrowth and Fig. 
6D for branching). Thus, NV polypeptides 
encoding the PBM sequence having a high 
affinity for MAST2-PDZ can still trigger 
neurite elongation, even if membrane 
anchorage is lost.  
To directly deliver NV3-Cyto into neurons as a 
peptide, we coupled the NV3-Cyto construct 
and its control, NV3-Cytoto a CPM, as 
displayed in Fig. 7A. We used the variable part 
(VHH) of a single-chain llama antibody as the 
CPM, because this molecule has been shown to 
cross the blood-brain barrier and the plasma 
membrane of brain cells (23,24). Constructs 
encoding CPM-NV3-Cyto and CPM-NV3-
Cyto as a control (CPM-Neurovita and CPM-
Neurovita respectively), were genetically 
engineered (Fig. 7A), expressed in bacterial 
periplasm and the resulting proteins were 
purified. We have previously shown that when 
CPM-Neurovita was added to a mixed culture 
of humans neurons, astrocytes and microglia 
CPM-Neurovita targets neurons preferentially 
(25). Here, we analyzed whether CPM-
Neurovita could be detected in NS by WB or 
flow cytometry after CPM-Neurovita was 
added to the culture medium (Fig S3). Six hours 
after the addition of CPM-Neurovita to the 
culture medium, CPM-Neurovita could be 
detected by WB in the cell lysates at the 
expected molecular weight of 22.7 kDa (Fig. 
S3A). Thirty minutes after the addition of CPM-
Neurovita to the culture medium, CPM-
Neurovita entry was detected by flow cytometry 
when the cells had been previously 
permeabilized (Fig. S3B, left panel) whereas no 
staining was observed on non-permeabilized 
cells (Fig. S3B, right panel). This indicates that 
CPM-Neurovita associates with some cellular 
area made accessible to the antibody by the 
permeabilization treatment such as the 
cytoplasm or the submembrane area.  
When added to the culture medium of NS cells, 
CPM-Neurovita (2.35 pg/cell) triggered 
stronger neurite outgrowth than the one 
observed for CPM-NeurovitaΔ-treated cells or 
non-treated cells (Fig. 7B). Time-lapse 
recordings over a period of 12 h (starting 18h to 
after treatment up to 30h post treatment) with 
Incucyte Technology were used to compare the 
speed of neurite growthThe number of neurites 
per neuron (Fig. 7C) and the speed of growth 
(Fig. 7D) were significantly greater in NS cells 
treated with CPM-Neurovita than in cells 
treated with CPM-Neurovita
Thus, NV efficacy is qualitatively maintained 
when the NV sequence is delivered as a cell-
penetrating interfering peptide. 
Discussion 
Protein-protein interaction domains including 
PDZ domains governing signaling pathways 
critical for cell homeostasis are emerging as 
promising targets for therapeutic applications 
(26-30). These signaling pathways can be 
manipulated with short interfering peptides, 
which disrupt these interactions. Viruses are 
obligate intracellular parasites, and their 
multiplication is dependent on cellular 
resources. The mimicry of PBM by viral 
proteins is a simple strategy by which several 
viruses take control of the cellular machinery. 
In particular, this mimicry enables some viruses 
to modify the commitment of infected cells to 
death or survival (16,31,32). Identification of 
the viral sequences involved and elucidation of 
their mechanisms of action could potentially 
facilitate the design of efficient interfering 
peptides. We have identified a viral protein, the 
RABV G-protein, that promotes neurite 
outgrowth by disrupting interactions between 
the PDZ of the MAST2 kinase and its 
endogenous ligands, such as PTEN, via its C-
terminal PBM.  In this study, we investigated 
whether we can leverage the robust strategy 
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evolved by a virus for ensuring its own 
propagation in the brain, to develop a short 
interfering peptide that promotes neurite 
outgrowth by specifically targeting MAST2-
PDZ.  
We hypothesized that NV peptides derived 
from the RABV G-protein and competing with 
the endogenous ligand for binding to the 
MAST2-PDZ domain would promote neurite 
outgrowth following their delivery into cells. 
We first showed that short peptides encoding 
the Cyto-domain of the G-protein reproduce the 
properties of RABV. However, the presence of 
certain parts of the viral RABV G-protein 
involved in association with endomembranes, 
such as the SP and TM domain, were necessary 
to insure their correct cellular targeting. The 
resulting interfering peptide, NV1, encodes a 
PBM bound to MAST2-PDZ with an affinity in 
the micromolar range similarly to PTEN, which 
is one of the endogenous ligands of MAST2-
PDZ. We suggested that increasing the affinity 
of the interfering peptide for MAST2-PDZ 
would increase the peptide potency to stimulate 
neurite outgrowth. We used structural, kinetic 
and thermodynamic data for a large number of 
PDZ/peptide complexes to design peptides with 
a higher affinity for MAST2-PDZ, with the viral 
and one endogenous partners of MAST2 (i.e. 
RABV G-protein and PTEN) as the starting 
material. One of the original features of our 
approach relates to the specificity of MAST2-
PDZ recognition. In addition to increasing the 
affinity of NV peptides for MAST2-PDZ, we 
also wished to maintain this specificity for 
MAST2-PDZ to prevent undesirable additional 
interactions with other endogenous proteins. 
PDZ binding selectivity seems to have been 
achieved throughout evolution (33,34). 
Extensive scans of random peptides against a 
large collection of PBM domains led to the 
definition of discrete sets of PDZ classes, 
conserved from worms to humans, 
encompassing the last seven amino-acid 
residues of potential PBM candidates (35). 
Most attempts to improve the strength of a given 
PDZ-PBM interaction have focused on 
modifications to the pre-existing stretch of 
seven amino-acid residues at the C-terminus of 
the PBM, position by position. Such efforts 
have generally resulted in a loss of the 
specificity of this interaction pair with respect 
to competing PDZ or PBM molecules (16,36-
38). Indeed, we previously showed that one 
mutation at position -3 in the PBM sequence of 
the RABV G-protein is sufficient to extend 
cellular protein recognition patterns and to 
switch cell fate from survival to death (16). We 
therefore decided to keep the COOH terminus 
QTRL> intact in the new NVs.  
Some PDZ domains make use of amino-acid 
sequences beyond the canonical PDZ domain 
fold, which are referred to as extended PDZ 
domains. Similarly, some PDZ ligands require 
extension sequences beyond the C-terminal 
PBM, including some more than 10 residues 
from the last C-terminal residue, for complex 
formation with the PDZ domain of the partner 
protein (38). We have shown that both RABV 
G-protein and PTEN make use of a PBM 
extension up to position -12 for binding to 
MAST2-PDZ (18,19). The unusually large 
interaction interface between MAST2-PDZ and 
G-protein or the PTEN C-terminus involves not 
only the four-amino acid canonical PBM, but 
also a two-amino acid N-terminal anchor (SW 
and PF for G-protein and PTEN, respectively). 
This N-terminal anchor increases MAST2 –
PDZ binding affinity and probably plays a 
crucial role in narrowing the specificity of 
interaction between MAST2 and its partners 
(18). This finding is reminiscent of observations 
from other studies indicating that PTEN also 
uses an N-terminal extension to bind the third 
PDZ domain of PAR-3, improving the 
specificity of PTEN for its target and its 
subcellular distribution at the junctional 
membrane of polarized cells (39). We suggested 
that in this case, the N-terminal anchor might be 
involved in PBM-PDZ specificity and might 
increase the affinity of the PBM for MAST2-
PDZ. We therefore did not modify this part of 
the molecule either.  
By conserving the two viral anchoring sites, 
NH2SW- and –QTRLCOOH, from virulent RABV 
strains, which promote neuron survival, we 
were able to conserve the specificity of NV 
peptides for MAST2-PDZ, as illustrated by 
high-throughput PDZome screening.  
We increased the affinity of NV peptides for 
MAST2-PDZ mostly by decreasing the entropic 
cost of binding by modulating the flexibility of 
the central linker connecting the two binding 
sites of NV peptides, thereby greatly increasing 
the residence time of NV on MAST2-PDZ. 
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After two rounds of optimization, we obtained 
peptides with an affinity 20 times higher 
(KD=60 nM) than that of the initial viral or 
endogenous peptides (1 300 nM). Such an 
affinity, in the nanomolar range, is particularly 
high for a PDZ/ligand system, especially for 
molecules targeting a single PDZ domain. For 
example, interfering peptides targeting the 
Disheveld PDZ and functioning as an inhibitor 
of the Wnt/beta-catenin signaling pathway or 
targeting the PDZ1 of PSD95 and functioning 
as an inhibitor of nitric oxide (NO) synthesis, 
have Kd values in the micromolar range (40-42). 
A few examples of nanomolar affinity (3-16 
nM) have been reported for multivalent 
inhibitors targeting multi-PDZ containing 
proteins, such as those targeting proteins of the 
MAGUK family (43).  
The selected peptides, NV 1, 2 and 3, are 
capable of inducing the neurite outgrowth of NS 
cells with an efficiency related to their affinity 
for MAST2-PDZ. These data strongly support 
our hypothesis that NVs activity can be 
increased by enhancing the strength of 
interaction with the cellular partner. 
Given their capacity to promote neuron 
survival, NVs could have therapeutic 
applications for diseases of the nervous system 
in which neuron survival is compromised. The 
different ways to deliver NVs will be 
determined by the nature of the disease. For 
chronic diseases, it may be advantageous to 
deliver NVs in gene form, via a viral vector, 
such as a lentivirus or an adeno-associated virus 
(AAV), which can transduce neurons. The 
delivery of a peptide, rather than a gene, may be 
more appropriate when a fast mode of action is 
required for example in the case of an acute 
nerve injury. We therefore tried to adapt NV 
sequences for peptide production, by reducing 
the peptide size, to facilitate production and 
delivery. 
We showed that for the optimized peptide NV3 
that the processing and translocation were 
dispensable. Thereby, we were able to halve the 
size of the peptides, while maintaining the 
activity of the original construct. However, the 
20-fold improvement in affinity initially 
achieved was counterbalanced by imperfections 
of targeting. This design was feasible only for 
NV3, the peptide with the highest affinity for 
the target. Indeed, our first attempt to generate 
a similar construct from the NV1 peptide 
resulted in a total loss of neurite outgrowth 
stimulation (data not shown). We subsequently 
demonstrated the feasibility of replacing the 
viral vector delivery system by fusing a 
shortened NV3 peptide to a CPM.  
In this study, resulting from a combination of 
biophysical and cellular approaches, we showed 
for the first time that a virus-derived peptide 
could be optimized to trigger neurite outgrowth, 
in several types of neurons. This work opens up 
a number of very promising perspectives for the 
use of NV as a potential drug candidate in 
neurodegenerative diseases.  
Experimental procedures 
Cell lines, plasmids encoding RABV G- 
protein sequences, lentivectors and CPM-
Neurovita  
Neuroscreen cells (NS), a subclone of rat 
pheochromacytoma 12, PC12, neuronal cells, 
were obtained from Cellomics (USA) and 
cultured according to the supplier’s 
instructions. NS cells were grown in non-
differentiating (NDF) medium (Roswell Park 
Memorial Institute 1640,  RPMI 1640 medium, 
Thermo Fisher Scientific France #11875093; 
5% foetal bovine serum, FBS; 10% horse 
serum; 1% 200 mM glutamine, Thermo Fisher 
Scientific France #25030149 and 1% 100 x 
Penicillin Streptomycin, Pen-Strep, Thermo 
Fisher Scientific France #15140148). The 
differentiating (DF) medium had the same 
composition with the addition of 200 ng/ml of 
nerve growth factor (NGF; SIGMA USA 
#N2513). A clone of the human SH-SY5Y 
neuroblastoma cell line, which was originally 
used to decipher the role of the kinome, 
including the role of MAST2, in neurite 
outgrowth, was obtained from Dr S.H. Loh and 
was grown as previously described (12). The 
NDF for these cells consisted of Dulbecco’s 
Modified Eagle Medium 12, DMEMF12 
(Thermo Fisher Scientific France # 31330038) 
supplemented with 10% FBS plus 1% 100 x 
Pen-Strep and 1% 200 mM glutamine. The DF 
medium for these cells was Neurobasal medium 
(Thermo Fisher Scientific France #21103049) 
supplemented with B27 medium (Thermo 
Fisher Scientific France #A3582801), 1% 100 x 
Pen-Strep, and 1% 200 mM glutamine and 1 
mM db-cAMP (Sigma-Aldrich USA #D06627). 
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 Cortical neurons were prepared from E16 
Swiss mice as described by S. Vitry et al. (44). 
Embryonic mouse brains were dissected in 
Hank’s Balanced Salt Solution, HBSS (Life 
Technologies #14175) supplemented with 10 
mM Hepes, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid,  (Life 
Technologies #15630), 0.05% glucose (Sigma 
#G8769) and 50 µg/ml gentamicin (Life 
Technologies #15750). Meninge-free brain 
cortices were collected in HBSS supplemented 
with 400 U/ml DNAse (Roche #04536282001) 
and incubated with the Liberase HD enzymatic 
cocktail (Sigma #5401054001). The digested 
tissues were triturated mechanically and the 
enzymatic reaction was stopped by adding FBS. 
The suspension was washed in HBSS and 
centrifuged for 5 min at 200 x g, and the 
resulting cell pellet was suspended in 
Neurobasal medium (Life Technologies 
#21103) supplemented with 25 nM 2-
mercaptoethanol (Sigma #M7522), 50 µg/ml 
gentamicin, 5 mM Hepes, 2 mM Glutamax 
(Life Technologies #35050), N2 (Life 
Technologies #17502) and B27 (Life 
Technologies #17504). Viable cells were used 
to seed the wells at a density of 104 to 3 x 104 
cells per cm2 on plates coated with poly-D-
lysine (Sigma #P6407) and laminin (Sigma 
#L2020). The cells were allowed to sediment, 
and to adhere for 20 min at room temperature. 
They were then transferred to an incubator 
containing 9% CO2 in air maintained at 37°C, 
for 40 min, before the addition of 10 µg/ml 
fluodeoxyuridine (Sigma #F0503) and 25 µg/ml 
uridine (Sigma #U3003). 
The iPSc clones (clone 2.1, (45) and clone 3.1, 
unpublished) were stimulated to differentiate 
into motor neurons as described by Maury et al. 
(46).  
The G-[SP-(2aa)-TM-Cyto] plasmid, which 
encompasses all the protein domains of the full-
length RABV G-protein (RABVvir strain) 2 
(signal peptide SP, transmembrane TM, 
cytoplasmic domain Cyto and the two amino 
acids (2aa) flanking the TM), was described in 
patent application WO2010/116258 (47). The 
nucleotide sequences of NV1, NV1Δ, NV2 and 
NV3 were obtained by PCR and inserted into 
the pLenti6.3/V5-TOPO® (Blasticidin) or 
pLenti7.3/V5-TOPO® (e-GFP) vector with the 
TA cloning kit (Invitrogen France # K5315-20). 
Lentiviruses were produced in 293T cells by 
standard procedures, as described by Zufferey 
R. et al. (48). The number of HIV particles was 
determined with the HIV p24 ELISA kit (Perkin 
Elmer USA # NEK 050B). The infectivity of 
recombinant lentivectors was systematically 
monitored by RT-qPCR and/or flow cytometry. 
The GenBank accession numbers of the 
lentivectors are: Lenti-NV1 (KJ742386), Lenti-
NV1Δ (KJ742387), Lenti-NV2 (MH197113) 
and Lenti-NV3 (MH197112). The CPM-
Neurovita) and its PBM-deleted counterpart 
(CPM-NeurovitaΔ) were described in European 
patent application EP14306388(49).  
CPM-Neurovita is a 209aa long (MW 
=22.7kDa) chimeric molecule consisting of i) 
Neurovita and ii) a CPM formed by a Neuro-
Tag domain (a RABV-derived peptide from the 
RABVvirG-Protein ectodomain that recognizes 
the AChR Alpha 7 subunit), and by the variable 
part (VHH) of a llama single-chain antibody 
capable of crossing biological membranes and 
the blood brain barrier (23), and iii) a StrepTag 
sequence to label the molecule. CPM-
NeurovitaΔ is the disabled form of the molecule 
with a deletion of the last 4 aa of the PBM. The 
GenBank accession numbers are KJ784393 
(CPM-Neurovita) and KJ784394 (CPM-
NeurovitaΔ). The genes were synthesized 
chemically (MWG Operon, Germany) and 
inserted into the pASK-IBA2 plasmid (IBA, 
BioTAGnology, Germany) under the control of 
the tetracycline promoter. The ompA signal 
sequence added by this plasmid directs the 
expressed protein into the periplasmic space of 
the bacteria and is cleaved during translocation. 
The recombinant plasmids were used to 
transform XL1-blue E. coli bacteria 
(Stratagene, USA). Recombinant bacteria were 
identified by PCR and glycerol stocks were 
generated. CPM-Neurovita peptides were 
expressed and purified from the bacterial 
periplasm as described by Lafaye et al. (50). 
The periplasmic extract was further purified by 
immunoaffinity chromatography with a mouse 
high-affinity anti-StrepTag IgG1 mAb, C23.21 
(kindly provided by Pierre Lafaye). The 
molecules were stored in 0.25 x PBS at -80°C. 
CPM expression was monitored by western 
blotting with the C23.21 mAb, with 
quantification by Odyssey Li-Cor infrared 
chemo luminescence (Li-Cor, USA) with a 
standardized VHH-StrepTag preparation.  
Neurite outgrowth 
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SH-SY5Y and NS cells: Neurite outgrowth 
assays on SH-SY5Y and NS were performed as 
described in detail by Loh S.H. et al. (12) and 
Prehaud C. et al. (16). Briefly, SH-SY5Y or NS 
cells were used to seed 24-well plates (CellBind 
plastic ware, Corning USA # 83-3337) 
containing non-differentiating medium, at a 
density of 40 000 cells per well. They were 
cultured overnight at 37°C. The medium was 
then replaced with DF medium and the cells 
were incubated for a further 6 h. They were then 
infected with 30 ng p24 lentiviral vector or 
treated with 2.35 pg/cell CPM-Neurovita or 
CPM-NeurovitaΔ in DF medium for 1 h. The 
cells were washed once with DF medium, and 
incubated in DF medium for 24 h at 37°C. 
Thirty hours (SH-SY5Y) or 72 h (NS) post 
transduction, the cells were fixed by incubation 
with 3% paraformaldehyde (PFA) in phosphate-
buffered saline (PBS, Thermo Fisher Scientific 
France # 14040141) for 20 min at room 
temperature and treated for 5 min with 0.1% 
Triton-X-100 and 50% normal goat serum 
(NGS) in PBS. Neuron-specific anti-βIII-
tubulin antibody (Promega France # G7121) 
and Hoechst 33342 (Thermo Fisher Scientific 
France #62249) were used to stain the neurite 
processes and the nuclei, respectively. 
Alternatively, the cells were also stained with 
crystal violet, which preserves the neurite 
processes. SH-SY5Y human neuroblastoma 
cells (30 fields, mean of 300 cells per field) and 
NS cells (36 fields, mean of 324 cells per field) 
were imaged with a Leica DM 5000B UV 
microscope equipped with a DC 300FX camera 
(x40 or x20 objective). The images were 
analyzed using ImageJ 1.38X Software (Wayne 
Rasband, NIH, USA, http://rsb.info.nih.gov/ij/) 
and its plug-in NeuronJ (51) 
(http://www.imagescience.org/meijering/softw
are/neuronj/). The effects of bias were 
minimized by performing the experiment blind, 
with relabeling of the samples. 
Motor neurons. Motor neurons were plated at a 
density of 10 000 cells per well (48-well plates). 
Gene transfer was performed with lentiviral 
vectors (six ng p24 per well) after the next day. 
Transduction was obtained in 80-90% of cells. 
Non-treated conditions was used as a quality 
control of the culture.  Cells were fixed three 
days later (4% PFA in PBS for 20 min at room 
temperature). The cells were washed in PBS and 
incubated for 1 h at room temperature in PBS 
containing 2% NGS, 1% bovine serum albumin 
(BSA, SIGMA USA # A2153) and 0.1% Triton 
X-100 (SIGMA USA # X100). Cells were then 
incubated overnight at 4°C with anti-βIII-
tubulin antibody (TUBB3, Biolegend France # 
801201), washed three times in PBS and 
incubated for 1 h at room temperature with 
Alexa Fluor 555-conjugated anti-mouse IgG2a 
antibody (Thermo Fisher Scientific # A-21137). 
Nuclei were stained with 1 mg/ml Hoechst 
H33342 (Thermo Fisher Scientific France 
#62249). Motor neurons (500 cells) were 
analyzed with the Cell Insight platform 
(Cellomics, Thermo Fisher Scientific France), 
using the Neuronal Profiling Bio-application 
suite. Neurite outgrowth phenotype was 
determined in triplicate experiments. 
Mouse cortical neurons. Mouse cortical neurons 
(3DIV) were plated on 96-well dark-sided cell-
binding plates (Corning USA #3340). They 
were infected with 10 ng p24/well of lentiviral 
vector 2 h after seeding. The medium was 
changed 12 h after infection. Three days post 
infection, the medium was carefully removed 
and the neurons were fixed by incubation with 
4% PFA for 20 min at room temperature. Plates 
were washed three times with PBS and the cells 
were permeated by incubation with 0.3 % Triton 
X-100 (SIGMA USA # X100) for 10 min at 
room temperature. Analysis of neuronal βIII 
tubulin immunofluorescence and Hoechst 
staining were performed as described above for 
SH-SY5Y/NS cells. Primary cortical neurons 
(10 fields, mean of 650 cells per field) were 
analysed with the Cell Insight platform 
(Cellomics, Thermo Fisher Scientific France), 
using the Neuronal Profiling Bio-application 
suite. Neurite outgrowth phenotype was 
determined in triplicate experiments. 
Time-lapse experiments in NS cells  
 We determined the neurite-bearing cell 
phenotype and assessed the speed of neurite 
outgrowth by using NS cells in NDF to seed 
collagen-coated 24-well plates (CellBind 
plastic ware, Corning USA # 83-3337) at a 
density of 40 000 cells per well. The cells were 
cultured overnight at 37°C. The NDF medium 
was replaced by DF medium containing only 10 
ng/ml of NGF and 7% FBS (52), 24 h after 
seeding, and the cells were incubated for a 
further 3 h. They were then treated with 700 
ng/well CPM-Neurovita or CPM-NeurovitaΔ in 
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DF medium. Cells were incubated in DF 
medium for 48 h at 37°C, under an atmosphere 
containing 5% CO2 in an IncuCyte Live-Cell 
analysis system. Images were recorded every 
hour over a two-day period. For live-cell 
imaging on IncuCyte, NS cells (nine fields 
mean of 43 cells per field) were recorded on 
bright-field images and analyzed with 
Fiji/ImageJ (https://fiji.sc/) and the NeuronJ 
plug-in. The percentage of neurite-bearing cells 
(53) and the speed of neurite outgrowth and 
elongation were monitored over 12 h, from 18 
to 30 h after treatment. 
 
Arborization analysis 
Sholl analysis (22,54) was used to assess 
dendritic arborization. This analysis was 
performed as described by Sahay A. et al. (22) 
and Lioy DT. et al. (55). Measurements were 
obtained from 8-bit converted images with the 
Sholl analysis plugin of Neuron J. (http://www-
biology.ucsd.edu/labs/ghosh/software/). 
Branching complexity was quantified by 
counting the intersection of neurites with each 
of 10 concentric circles of increasing radius 
drawn around the cell body. We picked 30 
neurons at random from each group for analysis. 
Experiments were performed at least three 
times. Bias was minimized by performing the 
experiments blind after sample relabeling. 
Reverse transcription and quantitative 
polymerase chain reaction 
The procedures used for reverse transcription 
and quantitative polymerase chain reaction 
(RT-qPCR) have been described elsewhere 
(56). Basically, cDNA was synthesized from 1 
μg total RNA with the SuperScript II reverse 
transcriptase (Thermo Fisher Scientific France 
#18064014). Quantitative real-time RT-PCR 
(RT-qPCR) was performed in triplicate with an 
ABI Prism 7500 fast sequence detector system 
with GoTaq PCR master mix (Promega France 
#M7133). After normalization against 18S 
rRNA, the relative abundance of mRNA was 
obtained by calculating the difference in 
threshold cycles between the test and control 
samples (mock value set at 1), as according to 
the ΔΔCT method. The primers used were  
Lenti-1 
(AGACGCCATCCACGCTGTTTTGACCTC
CATAG),  
Lenti-2 
(CCAAAACACAATGGAAAAACCAGAAG
GGGTAC), 
Lenti-3 
(GTGTTGCGTAGGTTCTGATCGATTGAC
TCTTC),  
18S (F: CTT AGA GGG ACA AGT GGC G; R: 
ACG CTG AGC CAG TCA GTG TA) 
MAST2: Quantitect primers (Qiagen, 
Germany) QT00042574. 
 
Western blotting (WB) 
Proteins were suspended in Radio 
Immunoprecipitation Assay, RIPA, buffer 
(Sigma USA #R0278) supplemented with 
Complete ULTRA EDTA (Roche USA 
#05892970001), PhosSTOP (Roche USA 
#04906845001) and nuclease (Thermo Fisher 
Scientific France #88701). Protein extracts 
were diluted in NuPAGE LDS buffer (Thermo 
Fisher Scientific France #NP0007) containing 
NuPAGE reducing agent (Thermo Fisher 
Scientific France #NP0004). Protein samples 
(15 µg/µl) were then loaded onto NuPAGE 
Novex 12% Bis-Tris gels (Thermo Fisher 
Scientific France #NP0341) and subjected to 
electrophoresis in MOPS SDS running buffer 
(Thermo Fisher Scientific France #NP0001). 
The protein bands were blotted onto PVDF 
Immobilon-FL membranes (Millipore France 
#IPFL00010). Membranes were blocked with 
5% BSA in PBS-T buffer (PBS with 0.1% 
Tween 20) and incubated overnight at 4°C with 
the primary antibody in blocking buffer 
containing 0.1% Tween 20 (SIGMA USA 
#P1379). The membrane was washed with 0.1% 
Tween 20 in PBS and the antigen/antibody 
complex was detected with a horseradish 
peroxidase (HRP)-conjugated secondary 
antibody. Membranes were washed with PBST 
and visualized with the ECL western blot kit 
(Thermo Fisher Scientific France #35055) on a 
G-Box (SYNGENE USA). The primary 
antibodies were the anti-βIII-tubulin (Promega 
France # G7121) and an anti-RABV G-cyto 
domain (produced in-house, NIV biological 
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collection) antibody. The secondary antibody 
was an HRP-conjugated anti-mouse IgG 
antibody (GE Healthcare U.K. #NA9310). 
MAST2 immunofluorescence in NS or SH-
SY5Y cells 
Neuronal cells were seeded on Poly-L-lysine-
Collagen coated glass slide (3e+04 cells per 
slide) in a 24-wells cell culture plate. Twenty-
four hours later, cells were rinsed with PBS 
buffer (3 times) and fixed with 100% methanol 
at -20°C for 20 min. Then cells were washed 
three times with PBS, blocked with 5% goat 
serum in PBS for an hour at room temperature, 
rinsed three times with PBS and incubated 
overnight at 4°C with the anti-MAST2 antibody 
(1/500, Thermo Fisher Scientific France #PA5-
75974) diluted in 5% goat serum in PBS. The 
day after, the glass slides were washed three 
times with PBS, incubated with the secondary 
antibody conjugated with AF555 (1/500, 
Thermo Fisher Scientific France #A27039) and 
Hoescht 33342 (Thermo Fisher Scientific 
France #H3570) for one hour at room 
temperature. Then the slides were washed three 
times with PBS and mounted with prolong gold 
(Thermo Fisher Scientific France #P36982). 
Cells were imaged with a Zeiss LSM70 
confocal UV microscope.  
Penetration of CPM-Neurovita in NS 
The flow cytometry procedures, have been 
described in Prehaud et al. (47,57). Briefly, 
NGF-treated (6 hours) NS cells which had been 
seeded on 6 well plates (0.5.e+06 cells per well) 
were treated with 20 ng of CPM-Neurovita or 
mock-treated with PBS buffer for 30 min at 
4°C. Then, cells were washed 3 times with PBS 
buffer before to be permeabilized to detect both 
the molecules bound to the membrane and the 
molecules in the cytoplasm. The CPM-
Neurovita molecules were detected with an 
anti-strep Tag mAb C23.2 (IP collection, Dr 
Pierre Lafaye) plus a Cy5 conjugated anti-
mouse antibody (Jackson laboratory, USA). 
For WB analyses, 1e+06 NS cells cultivated in 
NDF medium were processed as above after 
being treated with 9 µg of CPM-Neurovita or 
mock-treated with PBS buffer for 6 hours at 
37°C. Then cells were washed 3 times with PBS 
buffer, lysed with RIPA buffer and processed 
for WB using the anti-strep tag antibody C23.2.  
MAST2-silencing  
SH-SY5Y were silenced for the expression of 
MAST2 by using specific lentiviral shRNA 
MAST2 (TRCN0000001733, 
TRCN0000001735 and TRCN0000001736)   
and pL.KO1shRNA (RHS4080) as control. The 
lentiviral shRNA were found among the 
collection of the Open Biosystems Expression 
Arrest™ TRC library (Broad Institute MIT and 
Harvard, USA, sold by Thermofisher). 
Lentiviral shRNA viral stocks were produced as 
previously described. Briefly, SH-SY5Y (74  x 
106 cells in 12ml of medium) were infected with 
900ng of p24 equivalent of each lentiviral 
shRNA vector stock for two days. Then an 
aliquot of the cells was taken, total RNA was 
extracted and gene expression was monitored 
by Q-RTPCR. Neurite outgrowth was assayed 
in cultures exhibiting a knockdown of 
expression of >80%. Silencing experiment was 
conducted on triplicate individual samples.  
Statistical analysis 
ANOVA with Bonferroni’s multiple 
comparison post hoc-test and student’s T test 
were conducted with Graph Pad Prism version 
7 or 8 software. 
Sample preparation for biophysical methods 
MAST2–PDZ was expressed and purified as 
previously described (58). PBM peptides were 
synthesized on solid-phase supports, with the 
Fmoc (9-fluorenyl methoxycarbonyl) strategy 
(ProteoGenix; see Fig. 3B for sequences). All 
biophysics experiments were performed in 50 
mM Tris/HCl, 150 mM NaCl at pH 7.5. 
Isothermal titration microcalorimetry 
ITC measurements were performed as 
previously described (16) with VP-ITC and 
ITC200 calorimeters (Malvern). MAST2-PDZ 
(10 to 30M) was titrated at 298 K by 20 to 45 
consecutive injections of 2 to 7 μl aliquots of the 
peptides (110 to 280 M). Raw data were 
normalized and corrected for the heats of 
dilution of the peptides. Equilibrium 
dissociation constants were determined by 
fitting nonlinear curves to the corrected based 
on a model with one set of sites, with Origin7.0 
software (OriginLab). 
Stopped-flow experiments 
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The kinetics of association between MAST2–
PDZ and the NV3 peptide were studied at 20°C 
with SFM300 stopped-flow equipment with 
fluorescence detection (BioLogic). Typically, 
150 μl of MAST2–PDZ solution was rapidly 
mixed with an equal volume of peptide solution. 
For each peptide, three concentrations (2.5, 5 
and 10M) were tested at a constant MAST2–
PDZ–peptide ratio of 1:10 to respect pseudo-
first-order conditions. The maximal 
concentration of MAST2–PDZ was 1 μM. A 
mixing time of 15 ms was used (total flow rate 
of 20 ml·s−1), resulting in a dead time of 2.5 ms. 
Data points recorded between 0 and 3 ms were 
excluded from the fitting process. The flow cell 
was illuminated with a monochromatic UV 
light at 295 nm (bandwidth 8 nm) and emitted 
fluorescence was collected perpendicularly to 
the incident beam through a 325 nm high-pass 
filter. Kinetic data were acquired and analyzed 
as previously described (18). We stored and 
processed 10-12 averaged traces independently. 
Averaged kinetic traces from stopped-flow 
experiments were fitted independently with the 
following mono-exponential equation: 
F(t)=A·e−kobs·t + offset. For each peptide 
concentration, the mean values of amplitude, 
the observed rate constant and the 
corresponding SDs were calculated from the 
fitted values deduced from each series of 
averaged kinetic data. Intrinsic association and 
dissociation rate constants, kon and koff, were 
determined from the linear regression of the 
variation of kobs as a function of peptide 
concentration. 
Hold-up 
As described by Vincentelli R. et al. (20), 222 
PDZ domains clones from a complete collection 
of 266 PDZome clones were successfully 
expressed. The automated holdup assay 
protocol was performed on a Tecan freedom 
Evo200 machine with 384-well plates. A 41 M 
stock solution of biotinylated Neurovita peptide 
fixed on streptavidin beads was incubated with 
a 4M His-MBP-PDZ domain solution. After 
incubation, the liquid phase of the plates was 
collected and filtered and the concentration of 
unbound PDZ domains in the filtered flow-
throughs was measured by microfluidic 
capillary gel electrophoresis with a LabChip 
GX II machine (Caliper, PerkinElmer). Binding 
intensities (BIs) were calculated as described in 
the supplementary data of the paper by 
Vincentelli R. et al. (20). 
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Figure 1: Lentivector-delivered Neurovita 1 (NV1) in SH-SY5Y or NS triggers neurite outgrowth 
in a PBM dependent manner.  
A. Silencing of MAST2 (SH MAST2) triggers spontaneous neurite outgrowth in SH-SY5Y culture. This 
effect is not observed when cells were treated with pL.KO1shRNA (Control). Two-tailed unpaired 
Student’s t-test, =p<0.0001. These results are representative of two independent experiments. 
B. Structure of the RABV G-protein gene encoding a signal peptide (SP, 19 aa) an extracellular domain 
(EC), a transmembrane domain (TM, 22 aa) and a cytoplasmic domain Cyto (44 aa) together with a C-
terminal PBM. Scheme on the right shows G-protein trafficking from the ER to the plasma membrane 
in RABV-infected cells. Diagram of the lentiviral vector transgene expression cassettes: NV1 contains 
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the SP, two amino acids from the EC domain (2 aa), the TM, and the Cyto domain. NV1is identical 
except that it lacks the last 4 aa at the C-terminus of the PBM.  
C. Neurite outgrowth triggered by NV1 and NV1 in SH-SY5Y cells 24 h post transduction with the 
lentivectors. Left panel, expression of NV1 and NV1 assessed by WB with a RABV G-protein Cyto-
specific antibody. The expected MWs of NV1 and NV1 are 9.0 and 9.5 kDa, respectively. Expression 
of tubulin is used as a loading control. To note, NV1 and NV1 bands- obtained in the same membrane 
but on non-contiguous lanes- were spliced (dashed line).  Right panel, measurement of neurite outgrowth 
in SH-SY5Y cells expressing NV1 or NV1 30 h post-transduction. Images of 30 fields (mean of 300 
cells per field) were taken with a UV microscope for each condition. The images were analyzed by 
ImageJ and the NeuronJ plugin to calculate the average neurite length. N.T. = Non-Transduced cells. 
Results are representative of 6 independent experiments.  
 D. Neurite outgrowth triggered by NV1 and NV1 in NS cells 72 h post-transduction with the 
lentivectors. Left panel, protein levels assessed by WB. Expression of tubulin is used as a loading 
control. Right panel, measurement of neurite outgrowth in NS cells expressing NV1 or NV1 72 h post-
transduction. N=36 fields (mean number of cells per field: 324).  N.T. = non-transduced cells. Results 
are representative of 5 independent experiments.  
For C and D: ANOVA with Bonferroni’s multiple comparison post-hoc test, ****=p<0.0001.  
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Figure 2: NV1 stimulates neurite outgrowth in human iPSc-derived motor neurons and mouse 
cortical neurons.  
A. Neurite outgrowth in iPSc-derived human motor neurons expressing NV1 and NV1 72 h post-
transduction. Images of 6 fields (500 cells) were taken with the Cell Insight Platform. Analysis was 
performed using the Neuronal Profiling Bio-application. Neurite outgrowth was measured in triplicate 
wells.  Two-tailed unpaired Student’s t-tests **=p=0.0081. Scale bar = 20 µm. Results are representative 
of two independent experiments. 
B. Neurite outgrowth in mouse cortical neurons expressing NV1 and NV1 72 h post-transduction. 
Image of 10 fields (mean of 650 cells per field) were taken with the Cell Insight Platform. Neurite 
outgrowth was measured using the Neuronal Profiling Bio-Application. Neurite outgrowth was 
measured in triplicate experiments.  N.T.  = Non-Transduced cells, ANOVA with Bonferroni’s multiple 
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comparison post-hoc test, ****=p<0.0001. Scale bar =50 µm. Results are representative of two 
independent experiments. 
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Figure 3: Search for improved NV-PBMs 
A. Structure of MAST2-PDZ (in gray) bound to the viral peptide Cyto13 (PDB code 2KQL). The N-
terminal anchor, the linker, and the C-terminal anchor of Cyto13 are shown in blue, green and orange, 
respectively. The 13 C-terminal aa of NV1 and PTEN are indicated. 
 B. Thermodynamic parameters from ITC experiments for 11 peptides interacting with MAST2-PDZ.  
C. Enthalpy (H) and entropy (TS) values for peptides from the first and second rounds of optimization 
are shown in blue and orange, respectively. Values for NV1, 2 and 3, and PTEN peptides are indicated. 
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Figure 4. PDZome binding profiles for NV peptides. PDZ domains (x axis) are ranked in descending 
order of binding intensity (BI) (y axis). Magnifications showing the best binders of NV1, 2 and 3 (BI > 
0.2 IU). BI values greater than 0.6 IU, between 0.3 IU and 0.6 IU, and lower than 0.3 IU are shown in 
red, orange and yellow, respectively. Biotin was used as a control for the BI profile. 
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Figure 5: Increasing the affinity of NV-PBMs for MAST2 protein increases their biological activity 
A. Diagram of the lentiviral transgene expression cassettes showing the length of the cytoplasmic 
domain of the constructs (44 aa for the Cyto domain of NV1 and 42 aa for the Cyto domains of NV2 
and NV3). The PBM is underlined. Star * indicates the replacement or the deletion of one residue.  
 B. Transduction efficiencies for NV1, NV2 and NV3, as assessed by RT-PCR (left) or by WB on NS 
cells 48 h post-transduction with lentivectors. NT= Non-Transduced cells. Tubulin was used as a loading 
control.   
 C. Neurite outgrowth of NV3-, NV2-, NV1-, and NV1Δ-expressing NS cells 72 h post-transduction. 
N=20 fields (NV3, NV2, NV1), =10 fields (NV1Δ, N.T.). ANOVA with Bonferroni’s multiple 
comparison post-hoc test, ***=p=0.0002, ****=p<0.0001. Results are representative of three independent 
experiments. 
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D: Arborization (Sholl analysis) in NV3-, NV2- and NV1-expressing NS cells 72 h post-transduction. 
The analysis was performed in the same sets of NV1-, NV2- and NV3-treated NS cells. N=10 fields 
(NV3, NV2, NV1, NT) Two-way ANOVA ****=p<0.0008. Results are representative of three 
independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                  Interfering peptides stimulating neurite outgrowth 
 
 
26 
 
 
Figure 6: NV3-Cyto is as efficient as NV1  
A. Diagram of the two NV3 lentivector transgene constructs. NV3-Cyto is truncated and lacks the SP, 
the 2 aa from the EC domain, and the TM domain. It consists of the Cyto domain of NV3 only.  
B. Transcription of the NV3, NV3-Cyto and NV1 transgenes in NS cells. 18S is used as the standard. 
N=3. Two-tailed unpaired Student’s t tests, **=p=0.0017.  
C. Neurite outgrowth in NV3-, NV3-Cyto- and NV1-expressing NS cells 72 h post-transduction. NT 
=non-transduced cells. N=30 fields (NT, NV3-cyto), N=40 fields (NV1, NV2, NV3). ANOVA with 
Bonferroni’s multiple comparison post-hoc test. Two-tailed unpaired Student’s t-tests, ***=p=0.0002, 
****=p<0.0001. Results are representative of three independent experiments. 
D Arborization (Sholl analysis) for NV1- and NV3-Cyto-expressing NS cells 72 h post-transduction. 
NT = non-transduced cells. N=5 fields, two-way ANOVA. n.s= not significant. Results are 
representative of three independent experiments. 
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Figure 7. Delivery of Neurovita as a peptide using a CPM. 
A. Diagram of the CPM-Neurovita molecule and its PBM-deleted counterpart (CPM-NeurovitaΔ). 
CPM=Cell-Penetrating Molecule. 
B. Neurite outgrowth in CPM-Neurovita/CPM-NeurovitaΔ- transduced or non-transduced (NT) NS 
cells 72 h post treatment. N=13 fields (NT), N=6 fields (CPM-Neurovita), N=10 fields (CPM-
NeurovitaΔ). Two-tailed unpaired Student’s t-test, ****=p<0.0001. Results are representative of four 
independent experiments. 
C. NS neurite outgrowth was monitored by live-cell imaging on Incucyte (Sartorius, USA) in nine fields 
((mean of 43 cells per field) and analyzed with ImageJ and NeuronJ plugin. Percentage of neurite-
bearing NS cells (53) after treatment with either CPM-Neurovita or CPM-NeurovitaΔ. Over a 12 h time 
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period, from 18 h to 30 h post treatment, CPM-Neurovita triggered neurite outgrowth in NS cells in a 
PDZ-BM-dependent manner. The marks correspond to the percentages of neurite bearing cells observed 
every hour over the 12 hours period in CPM-Neurovita treated culture (left) or in CPM-Neurovita 
treated culture (right).  Two-way ANOVA, p<0.0001. Results are representative of two independent 
experiments. 
D: Over this 12-hour period, the speed of outgrowth, expressed as µm/hour, was monitored on the 
recorded live cell images. CPM-Neurovita increased the speed of neurite outgrowth in the NGF-treated 
NS cells. Two-tailed unpaired Student’s t-tests, p=0.0005. Results are representative of two independent 
experiments. 
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Supporting Information  : Structure-based optimization of a PDZ binding 
motif within a viral peptide  stimulates neurite outgrowth. Khan Z. et al, 
revision July 2019 
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Figure S1. Relevance of the in vitro biological models 
A. Detection of MAST2mRNA by Q-PCR. The ΔCt is the Ct obtained for MAST2 minus the Ct of the 
reference gene (18S). In these conditions the transcripts of a gene is considered non-detected for a 
ΔCt>22.  
B. Immunofluorescence detection of MAST2 protein in neuronal cells, SK-N-SH (left) and NS cells 
(right). MAST2 is in red, nuclei are in blue. Bars are 10µm. Two-tailed unpaired Student’s t-test, 
=p<0.0001. These results are representative of two independent experiments. 
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Figure S2. Representative NeuronJ tracing of the NS cells phenotypes following lentivectors 
delivery of NV molecules.  
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Figure S3. CPM-Neurovita associates with cells when added to the culture medium  
A. Western blotting detection of CPM-Neurovita in NS cells 6 hours after treatment with the CPM-
Neurovita (CPM-NV) or mock-treated. The control CPM-Neurovita is a loading control. These results 
are representative of two independent experiments.  
B. Flow cytometry detection of CPM-Neurovita after 30mn treatment (4°C) of NGF differentiated NS 
cells. The internal staining is shown on the left, the surface staining on the right. Black histogram 
represents the control condition. The cells treated with CPM-Neurovita correspond to the red solid line. 
These results are representative of two independent experiments. 
 
